Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ctrv.2022.102427 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of trilaciclib administered before chemotherapy in patients with extensive-stage small-cell lung cancer: A pooled analysis of four randomized studies.
Cancer Treat Res Commun
January 2025
JILIN Cancer Hospital, Changchun, PR China. Electronic address:
Background: Trilaciclib is a transient cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that reduces the incidence of chemotherapy-induced myelosuppression (CIM). In this pooled analysis, we evaluated the multilineage myeloprotection, antitumor efficacy, and safety of trilaciclib treatment in patients with extensive-stage small-cell lung cancer (ES-SCLC). Moreover, myeloprotection effect in 1 L, 2 L/3 L population and effect by risk category were explored.
View Article and Find Full Text PDFTelpegfilgrastim for chemotherapy-induced neutropenia in breast cancer: A multicenter, randomized, phase 3 study.
Chin Med J (Engl)
January 2025
Xiamen Amoytop Biotech Co., LTD, Xiamen, Fujian 361000, China.
Prognostic role of midregional proadrenomedullin in predicting infection in pediatric cancer with febrile neutropenia.
Clin Exp Pediatr
January 2025
Department of Pediatrics, Faculty of Medicine, Menoufia University, Shebin Elkom, Egypt.
Background: Febrile neutropenia (FN) remains an important complication of cytotoxic chemotherapy for which an urgent and appropriate evaluation is imperative.
Purpose: To assess the diagnostic and prognostic roles of mid-regional pro-adrenomedullin (MR-ProADM) levels in predicting infection in patients with FN.
Methods: This comparative cross-sectional study included 137 patients with chemotherapy-induced FN.
Usefulness of mid-regional pro-adrenomedullin for stratifying risk in emergency department patients with solid tumors attended for febrile neutropenia secondary to chemotherapy.
Emergencias
December 2024
Servicio de Análisis Clínicos, Hospital Universitario Santa Lucía, Cartagena, Murcia, España.
Objective: To analyze the usefulness of mean mid-regional pro-adrenomedullin (MR-proADM) level to stratify risk in emergency department patients with solid tumors attended for febrile neutropenia after chemotherapy. To compare risk prediction with MR-proADM to that of conventional biomarkers and scores on the Multinational Association for Supportive Care in Cancer (MASCC) score.
Methods: Prospective observational cohort study enrolling patients with solid tumors who developed febrile neutropenia after chemotherapy.
Background: Neutropenia and febrile neutropenia (FN) are serious complications of myelosuppressive chemotherapy and present a considerable burden to patients with cancer. Febrile neutropenia is associated with increased risks of infection and hospitalization, a particular concern during the coronavirus disease 2019 (COVID-19) pandemic. Oncology nurses and advanced practice providers (APPs; including nurse practitioners, physician assistants, advanced practice nurses, and pharmacists) play a vital role in the management of patients with cancer and the prevention of infections.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!